+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a combination of anti-malarial drugs in children aged 2 to under 12 years with uncomplicated Plasmodium falciparum malaria. This phase 2 platform study compares a single oral dose of up to three anti-malarial agents given together to the standard treatment known as Coartem. The study aims to better understand how these treatments work and their safety profiles in this young population. Participants are randomly assigned to one of two groups one receiving an oral combination of KLU156 with KAE609 alongside a light meal, and the other receiving the standard of care, Artemether plus lumefantrine, given orally according to the usual guidelines. This open-label, two-arm study monitors each treatment groups response to therapy. Throughout the study, participants undergo evaluations including parasite clearance times and blood tests to measure drug levels over the first week, with the main outcome assessed on day 29 using PCR to confirm clinical and parasitological response. Safety and tolerability are also closely monitored, and the total duration of participation extends up to 29 days after treatment initiation to assess treatment outcomes comprehensively.

Age: 2Years - 12YearsAll GendersPhase 2
13 locations
S

Actively Recruiting

Researchers are evaluating how well different anti-malarial drugs work and how safe they are for treating uncomplicated Plasmodium falciparum malaria in adults, adolescents, and children. This study focuses on the parasite-killing effects and potential cure rates of these drugs when given alone or combined with others. It also looks at how the drugs are processed by the body to help decide doses for future studies. Participants will receive one of several treatments, including varying doses of the oral drug INE963, combinations of oral KAE609 Cipargamin with INE963 or KLU156, or the standard of care drug Coartem. The study has multiple parts with patients allocated randomly to different treatment groups. Dosing levels and combinations are tested to compare how effectively they clear the malaria parasite. During the study, participants will have their parasite levels monitored up to 7 days and clinical response assessed by day 29. Blood samples will be taken by day 22 to study drug levels and how the body absorbs and clears the medicines. Safety is monitored through reports of side effects until day 43. The total participation lasts through these assessments to understand treatment impact and tolerability.

Age: 2Years - 100YearsAll GendersPhase 2
12 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of antimalarial drugs for treating uncomplicated malaria during the first trimester of pregnancy, a critical period for both mother and baby. The study compares the current standard treatment, artemether-lumefantrine AL, with newer antimalarials like pyronaridine-artesunate PA and dihydroartemisinin-piperaquine DP that have shown promise in earlier studies. The goal is to confirm if these newer drugs work as well as AL and are safe for pregnancy outcomes, while offering benefits such as simpler dosing and longer protection against new infections. The trial uses a Bayesian Adaptive Platform design that allows adding new treatments over time and stopping arms early if safety concerns arise. Pregnant women diagnosed with uncomplicated malaria in their first trimester are randomly assigned to receive AL twice daily for 3 days, or PA or DP once daily for 3 days with weight-based dosing. The study is open-label and conducted in multiple African countries where malaria is common. Participants will be monitored closely with daily visits for 4 days, weekly visits for 6 weeks, followed by monthly visits until delivery. Health and pregnancy outcomes will be tracked, and newborns followed for 6 months after birth. Safety data will be reviewed regularly by an independent monitoring board. The primary measure of success is the clinical and parasitological response at day 42. This research aims to expand safe treatment options for malaria in early pregnancy and improve health outcomes for mothers and babies in malaria-affected regions.

Age: 16Years +FEMALEPhase 3
3 locations